Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 13/20 | 0.67 |
| ▸ | CHRNA4 | P43681 | 13/20 | 0.67 |
| ▸ | CHRNB4 | P30926 | 12/20 | 0.58 |
| ▸ | CHRNA3 | P32297 | 12/20 | 0.58 |
| ▸ | CHRNA7 | P36544 | 12/20 | 0.58 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20592070 | 0.98 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL22631381 | 0.87 | NR1H2 (0.59) | CHRNB2CHRNA4NR1H2KDM4EEPHX2 | |
| SCHEMBL22630718 | 0.87 | NR1H2 (0.59) | CHRNB2CHRNA4NR1H2KDM4EEPHX2 | |
| SCHEMBL16249915 | 0.85 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL13150521 | 0.84 | NR1H2 (0.56) | CHRNB2CHRNA4NR1H2KDM4EEPHX2 | |
| SCHEMBL649983 | 0.82 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL17112600 | 0.82 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL584860 | 0.82 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL16053523 | 0.82 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL14222418 | 0.82 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132139-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| EP-4692076-A1 | HIV INHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12479853-B2 | HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-12479845-B2 | Imidazopyridine derivative compounds and use of same | HANMI PHARM. CO., LTD. (KR) | 2025-11-25 | — | — | US | disclosed |
| EP-3909949-B1 | ATAZANAVIR (ATV) ANALOGUES FOR TREATING HIV INFECTIONS | GILEAD SCIENCES INC (US) | 2025-10-15 | — | — | EP | disclosed |
| EP-4539840-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | Neuron23, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119730846-A | Kinase modulators and methods of use thereof | 神经元23公司 | 2025-03-28 | — | — | CN | disclosed |
| US-20250042910-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2025-02-06 | — | — | US | disclosed |
| EP-3681877-B1 | PYRAZOLE DERIVATIVE COMPOUND AND USE THEREOF | HANMI PHARMACEUTICAL CO LTD (KR) | 2024-10-16 | — | — | EP | disclosed |
| EP-1289996-A1 | HETEROARYLDIAZABICYCLOALKANES AS NICOTINIC CHOLINERGIC RECEPTOR LIGANDS | Targacept, Inc. (US) | 2003-03-12 | — | — | EP | disclosed |
| US-6492382-B1 | Dried or frozen pharmaceutical preparation containing a class III antiarrhythmic compound | ASTRAZENECA AB (SE) | 2002-12-10 | — | — | US | disclosed |
| US-6440970-B1 | ACTIVATING NICOTINIC CHOLERGINIC RECEPTORS | TARGACEPT, INC. | 2002-08-27 | — | — | US | disclosed |
| US-20020013309-A1 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. | 2002-01-31 | — | — | US | disclosed |
| WO-2001090109-A1 | HETEROARYLDIAZABICYCLOALKANES AS NICOTINIC CHOLINERGIC RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2001-11-29 | — | — | WO | disclosed |
| US-6291475-B1 | 3,7-DIAZABICYCLO(3.3.1)NONANE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-09-18 | — | — | US | disclosed |
| EP-1047695-A1 | NOVEL BISPIDINE ANTIARRHYTHMIC COMPOUNDS | AstraZeneca AB (SE) | 2000-11-02 | — | — | EP | disclosed |
| EP-1043997-A1 | A DRIED OR FROZEN PHARMACEUTICAL PREPARATION CONTAINING A CLASS III ANTIARRHYTHMIC COMPOUND | AstraZeneca AB (SE) | 2000-10-18 | — | — | EP | disclosed |
| WO-2000021533-A1 | A DRIED OR FROZEN PHARMACEUTICAL PREPARATION CONTAINING A CLASS III ANTIARRHYTHMIC COMPOUND | ASTRAZENECA AB (SE) | 2000-04-20 | — | — | WO | disclosed |
| WO-1999031100-A1 | NOVEL BISPIDINE ANTIARRHYTHMIC COMPOUNDS | ASTRAZENECA AB (SE) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479853-B2 | HIV inhibitor compounds | NFATC1, SAMHD1, CCR5 | CHRNB2 4877/4885CHRNA4 4843/4885CHRNB4 4872/4885 |
| US-20260132139-A1 | HIV INHIBITOR COMPOUNDS | SLC11A2, SLC6A15, NHERF1 | CHRNB2 4706/4885CHRNA4 4815/4885CHRNB4 4775/4885 |
| US-12479845-B2 | Imidazopyridine derivative compounds and use of same | KDM1A, KDM1B, KDM2A | CHRNB2 1569/4885CHRNA4 1210/4885CHRNB4 2168/4885 |
| US-20250042910-A1 | HIV INHIBITOR COMPOUNDS | NFATC1, SAMHD1, CCR5 | CHRNB2 4877/4885CHRNA4 4843/4885CHRNB4 4872/4885 |
| US-20020013309-A1 | Pharmaceutical compositions and methods for use | CYP2D6, CYP3A5, CYP2B6 | CHRNB2 359/4885CHRNA4 385/4885CHRNB4 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.